Logo image
Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators
Journal article   Open access   Peer reviewed

Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators

Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators
JAMA : the journal of the American Medical Association, Vol.279(16), pp.1265-1272
04/01/1998
DOI: 10.1001/jama.279.16.1265
PMID: 9565006
url
https://doi.org/10.1001/jama.279.16.1265View
Published (Version of record) Open Access

Abstract

CONTEXT Anticoagulation with unfractionated heparin is used commonly for treatment of acute ischemic stroke, but its use remains controversial because it has not been shown to be effective or safe. Low molecular weight heparins and heparinoids have been shown to be effective in preventing deep vein thrombosis in persons with stroke, and they might be effective in reducing unfavorable outcomes following ischemic stroke.

Details

Metrics

Logo image